Erlotinib induced skin rash spares skin in previous radiotherapy field.
Mitra
Sankha S
SS
Simcock
Richard
R
D000230:Adenocarcinoma / Q000188:drug therapy / Q000532:radiotherapy* / Q000556:secondary / Q000601:surgery; D001415:Back; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy / Q000556:secondary; D017024:Chemotherapy, Adjuvant; D003875:Drug Eruptions / Q000209:etiology / Q000517:prevention & control*; D000069347:Erlotinib Hydrochloride; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy* / Q000601:surgery; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000628:therapy; D011013:Pneumonectomy; D047428:Protein Kinase Inhibitors / Q000009:adverse effects; D011799:Quinazolines / Q000008:administration & dosage / Q000009:adverse effects*; D018714:Radiotherapy, Adjuvant; D012086:Reoperation; D012867:Skin / Q000187:drug effects / Q000528:radiation effects*; D035441:Thoracic Wall
D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D000069347:Erlotinib Hydrochloride